BioXcel Therapeutics, Inc. (BTAIQ) Free cash flow 2018–2025
BioXcel Therapeutics, Inc. (BTAIQ) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$57.6MFY2025 · since FY2018: -$13.8M → -$57.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$57.6M | +20.0% |
| FY2024 | -$72.0M | +53.5% |
| FY2023 | -$155.0M | -14.4% |
| FY2022 | -$135.5M | -64.0% |
| FY2021 | -$82.6M | -23.9% |
| FY2020 | -$66.7M | -138.3% |
| FY2019 | -$28.0M | -102.0% |
| FY2018 | -$13.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Gross marginBTAIQ Operating incomeBTAIQ Operating marginBTAIQ Operating cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Total liabilitiesBTAIQ Shareholders’ equityBTAIQ overview →